Seeking Alpha

Amylin Pharmaceuticals (AMLN +10.8%) continues to soar (previously) following the FDA's approval...

Amylin Pharmaceuticals (AMLN +10.8%) continues to soar (previously) following the FDA's approval of its Bydureon diabetes drug, developed in partnership with Alkermes (ALKS +1.3%). Piper (Overweight) thinks Bydureon's dosing flexibility gives it an edge over Novo Nordisk's (NVO) Victoza drug, and that FDA approval paves the way for an international licensing deal or acquisition.
Comments (1)
  • jeichmeier
    , contributor
    Comments (5) | Send Message
     
    See my comments under "Amylin Gets Its Yes; Now For The Hard Work" article. In time Bydureon will take over market due to dosing schedual and less side effects.
    2 Feb 2012, 02:37 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector